[HTML][HTML] Apremilast pharmacogenomics in Russian patients with moderate-to-severe and severe psoriasis
DA Verbenko, AE Karamova, OG Artamonova… - Journal of Personalized …, 2021 - mdpi.com
One of the target drugs for plaque psoriasis treatment is apremilast, which is a selective
phosphodiesterase 4 (PDE4) inhibitor. In this study, 34 moderate-to-severe and severe …
phosphodiesterase 4 (PDE4) inhibitor. In this study, 34 moderate-to-severe and severe …
[HTML][HTML] Plasma Cytokines for the Prediction of the Effectiveness of TNFα Inhibitors Etanercept, Infliximab, and Adalimumab in the Treatment of Psoriasis
A Karamova, L Znamenskaya, A Vorontsova… - Journal of Clinical …, 2024 - mdpi.com
Background/Objectives: Psoriasis is a chronic, inflammatory, immuno-mediated cutaneous
disease characterized by a prominent TNFα-IL23/IL17 immune axis. In recent years …
disease characterized by a prominent TNFα-IL23/IL17 immune axis. In recent years …
Effect of PUVA and NB‐UVB Therapy on the Skin Cytokine Profile in Patients with Mycosis Fungoides
AE Karamova, DA Verbenko, AA Vorontsova… - Journal of …, 2022 - Wiley Online Library
Background. Mycosis fungoides (MF) is the most common subtype of cutaneous T‐cell
lymphoma. The aim of the present study was to produce up‐to‐date information on different …
lymphoma. The aim of the present study was to produce up‐to‐date information on different …
[PDF][PDF] Expression dynamics of cytokine genes is related to the apremilast treatment effectiveness in patients with severe psoriasis
DA Verbenko, AE Karamova, OG Artamonova… - romj.org
Background—Psoriasis is an immune-mediated genetic skin disease with a deregulated
immune response governed by a proinflammatory cytokine network. Apremilast has …
immune response governed by a proinflammatory cytokine network. Apremilast has …
The Effect of Janus Kinase Inhibitors and Phosphodiesterase-4 Inhibitors on Skin and Plasma Cytokine Levels in Patients with Psoriasis
OG Artamonova, AE Karamova, AA Nikonorov… - Bulletin of Experimental …, 2021 - Springer
In patients with moderate-to-severe and severe psoriasis and high efficacy of therapy
(PASI≥ 75) with signaling pathway inhibitors (apremilast, tofacitinib), cytokine spectra in the …
(PASI≥ 75) with signaling pathway inhibitors (apremilast, tofacitinib), cytokine spectra in the …
Влияние селективных блокаторов янус-киназ и фосфодиэстеразы 4-го типа на концентрацию цитокинов в коже и крови больных псориазом
ОГ Артамонова, АЭ Карамова, АА Никоноров… - … биологии и медицины, 2021 - elibrary.ru
С использованием технологии xMAP определён спектр цитокинов в плазме крови и
коже больных псориазом среднетяжёлой и тяжёлой степени с высокой клинической …
коже больных псориазом среднетяжёлой и тяжёлой степени с высокой клинической …